Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16914843 | 0.80 | KDM4E (0.54) | KDM4EAKR1B1TAAR1GAARXFP1 | |
| SCHEMBL31568330 | 0.80 | KDM4E (0.54) | KDM4EAKR1B1TAAR1GAARXFP1 | |
| SCHEMBL31503471 | 0.79 | TAAR1 (0.56) | KDM4EAKR1B1TAAR1GAARXFP1 | |
| SCHEMBL139624 | 0.76 | PTGS1 (0.53) | KDM4ETAAR1GAARXFP1LMNA | |
| SCHEMBL16914878 | 0.75 | KDM4E (0.49) | KDM4EAKR1B1TAAR1GAARXFP1 | |
| SCHEMBL13090180 | 0.74 | KMT2A (0.49) | AKR1B1TAAR1GAALMNAKMT2A | |
| SCHEMBL14601735 | 0.73 | KDM4E (0.55) | KDM4EAKR1B1TAAR1GAARXFP1 | |
| SCHEMBL27635788 | 0.72 | TAAR1 (0.57) | KDM4ETAAR1GAALMNAHTT | |
| SCHEMBL3040407 | 0.71 | TAAR1 (0.61) | KDM4ETAAR1GAARXFP1LMNA | |
| SCHEMBL28596017 | 0.69 | TAAR1 (0.63) | KDM4ETAAR1GAALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654232-A4 | SULFONYL SUBSTITUTED N-(BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES | MERCK & CO INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7332499-B2 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO., INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK SHARP & DOHME CORP. | 2006-11-02 | — | — | US | disclosed |
| EP-1654232-A1 | SULFONYL SUBSTITUTED N-(BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016886-A1 | SULFONYL SUBSTITUTED N-(BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES | MERCK & CO., INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | BDKRB1, BDKRB2, CNR2 | KDM4E 3181/4885AKR1B1 1118/4885TAAR1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.